CSF2 and melanoma: Subcutaneous administration of GM-CSF at a dose of 125 μg/m2 for 14 days in different cycles for a year has been shown to prolong survival by two years in patients with surgically resected stage III/IV melanoma in comparison to patients who did not receive GM-CSF (95, 96).